{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_2009_0233968_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"039-894-257-659-507","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8906,"type":"PATENT","title":"Univ Pennsylvania Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":24238,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8221,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
wherein:\n\nR0 is alkylidene;\nR1 is NH(aralkyl), NHSO2aryl, NHSO2alkyl, CH2C(═O)alkoxy, NHC(═O)aralkoxy, or NHSO2R2;\nR2 is aryl, alkyl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino;\nEach R3 is independently halo, nitro, aryl, amino, alkyl, alkoxy, NH-Boc, alkylsulfonyl, NHC(═O)alkyl, NHC(═O)aralkyl, or NHC(═O)arylamino;\nEach R4 is independently amino, hydroxy, aralkoxy, NH(aryl), or NHC(═O)aryl;\nR5 is H or alkyl;\nR6 is H or ═O;\nA is SO2, PO2, CO2, or C═O;\nD is optional and may be one or more CH2 groups;\nE is aryl or heteroaryl;\nn is 0, 1, or 2;\nm is 0 or 1;\none of the three dashed-line portions may represent a double bond, and,\nq is 0, 1, 2, or 3;\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 1, wherein:\n
R1 is NH(aralkyl), NHSO2aryl, CH2C(═O)alkoxy, or NHC(═O)aralkoxy;\n
Each R4 is independently hydroxy or aralkoxy;\n
A is SO2, CO2, or C═O; and,\n
E is aryl;\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["A composition comprising a stereochemically enriched mixture of compounds according to claim 1."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 1, where A is C═O or CO2 and E is phenyl."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 1, where A is SO2."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 6, where E is phenyl and D represents a bond between A and E."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 7, where n equals 0."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 7, where n=1."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 9, where R3 is amino, acetamino, nitro, methyl, phenyl, benzyl, NHC(═O)benzyl, NHC(═O)phenylamino, or methylsulfonyl."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 10, where R1 is NH(aralkyl), NHSO2aryl, CH2C(═O)alkoxy, or NHC(═O)aralkoxy."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 9, wherein R3 is nitro and R1 is —NH(aralkyl), —NHSO2aryl, CH2C(═O)alkoxy, or —NHC(═O)aralkoxy."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 7, where n=2."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 13, wherein R3 is alkyl or halo, R1 is NH(aralkyl), NHSO2aryl, CH2C(═O)alkoxy, or NHC(═O)aralkoxy."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 1, wherein the compound is:3-tert-Butoxycarbonylamino-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-Benzyloxycarbonylamino-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-Benzoylamino-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-phenyl-propionylamino)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-pentanedioic acid 5-tert-butyl ester;3-[3-(2-Chloro-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Bromo-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-phenyl-ureido)-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-[3-(4-nitro-phenyl)-ureido]-propionic acid;3-(3-Biphenyl-4-yl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Methoxy-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(2-Methoxy-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(3-Methoxy-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Biphenyl-4-ylmethyl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-propyl-ureido)-propionic acid;3-(3-tert-Butyl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-tert-Butoxycarbonylamino-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Amino-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;2-{[1-(4-Acetylamino-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-benzyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-[(1-phenylmethanesulfonyl-pyrrolidine-2-carbonyl)-amino]-propionic acid;2-[2-(3-Benzyl-ureido)-1-carboxy-ethylcarbamoyl]-pyrrolidine-1-carboxylic acid benzyl ester;3-(3-Benzyl-ureido)-2-{[1-(biphenyl-4-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Amino-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-benzyl-ureido)-propionic acid;2-[(1-Benzoyl-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(toluene-4-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(naphthalene-1-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(naphthalene-2-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Amino-benzyl)-ureido]-2-[(1-benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-dimethyl-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(4-phenylacetylamino-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-({1-[4-(3-phenyl-ureido)-benzenesulfonyl]-pyrrolidine-2-carbonyl}-amino)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(naphthalene-2-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-[3-(2-chloro-benzyl)-ureido]-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-phenyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-phenyl-propionylamino)-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-benzoylamino-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-benzyloxycarbonylamino-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-[3-(2-methoxy-benzyl)-ureido]-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-[3-(3-methoxy-benzyl)-ureido]-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-propyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-difluoro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(4-methanesulfonyl-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-tert-butyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-4-benzyloxy-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-4-hydroxy-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-bis-trifluoromethyl-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-piperidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-2,5-dihydro-1H-pyrrole-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid; or,2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating at least one integrin α2β1-affected disease state or infection comprising the step of administering to a subject in need thereof a composition comprising a therapeutically effective amount of a compound having the formula:\n
wherein:\n\nR0 is alkylidene;\nR1 is NH(aralkyl), NHSO2aryl, NHSO2alkyl, CH2C(═O)alkoxy, NHC(═O)alkyl, NHC(═O)alkoxy, NHC(═O)aralkoxy, NHSO2R2, or NHC(═O)R2;\nR2 is aryl, alkyl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino;\nEach R3 is independently halo, nitro, aryl, amino, alkyl, alkoxy, NH-Boc, alkylsulfonyl, NHC(═O)alkyl, NHC(═O)aralkyl, or NHC(═O)arylamino;\nEach R4 is independently amino, hydroxy, aralkoxy, NH(aryl), or NHC(═O)aryl;\nR5 is H or alkyl;\nR6 is H or ═O;\nA is SO2, PO2, CO2, or C═O;\nD is optional and may be one or more CH2 groups;\nE is aryl or heteroaryl;\nn is 0, 1, or 2;\nm is 0 or 1;\none of the three dashed-line portions may represent a double bond, and,\nq is 0, 1, 2, or 3;\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16 comprising the step of administering to a subject in need thereof a composition comprising a therapeutically effective amount of a compound having the formula:\n
wherein:\n\nR1 is NH(aralkyl), NHSO2aryl, CH2C(═O)alkoxy, NHC(═O)alkoxy, NHC(═O)aralkoxy, or NHC(═O)R2;\nR2 is aryl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino;\nEach R4 is independently hydroxy or aralkoxy;\nA is SO2, CO2, or C═O; and,\nE is aryl;\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16 wherein the subject is administered a therapeutically effective amount of:3-tert-Butoxycarbonylamino-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-Benzyloxycarbonylamino-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-Benzoylamino-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-phenyl-propionylamino)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-pentanedioic acid 5-tert-butyl ester;3-[3-(2-Chloro-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Bromo-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-phenyl-ureido)-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-[3-(4-nitro-phenyl)-ureido]-propionic acid;3-(3-Biphenyl-4-yl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Methoxy-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(2-Methoxy-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(3-Methoxy-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Biphenyl-4-ylmethyl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-propyl-ureido)-propionic acid;3-(3-tert-Butyl-ureido)-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-tert-Butoxycarbonylamino-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Amino-benzyl)-ureido]-2-{[1-(4-nitro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;2-{[1-(4-Acetylamino-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-benzyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-[(1-phenylmethanesulfonyl-pyrrolidine-2-carbonyl)-amino]-propionic acid;2-[2-(3-Benzyl-ureido)-1-carboxy-ethylcarbamoyl]-pyrrolidine-1-carboxylic acid benzyl ester;3-(3-Benzyl-ureido)-2-{[1-(biphenyl-4-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-{[1-(4-Amino-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-3-(3-benzyl-ureido)-propionic acid;2-[(1-Benzoyl-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(toluene-4-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(naphthalene-1-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(naphthalene-2-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-[3-(4-Amino-benzyl)-ureido]-2-[(1-benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-dimethyl-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(4-phenylacetylamino-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-({1-[4-(3-phenyl-ureido)-benzenesulfonyl]-pyrrolidine-2-carbonyl}-amino)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(naphthalene-2-sulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-[3-(2-chloro-benzyl)-ureido]-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-phenyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-phenyl-propionylamino)-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-benzoylamino-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-benzyloxycarbonylamino-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-[3-(2-methoxy-benzyl)-ureido]-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-[3-(3-methoxy-benzyl)-ureido]-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-propyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-difluoro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(4-methanesulfonyl-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-tert-butyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-4-benzyloxy-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-4-hydroxy-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;3-(3-Benzyl-ureido)-2-{[1-(3,5-bis-trifluoromethyl-benzenesulfonyl)-pyrrolidine-2-carbonyl]-amino}-propionic acid;2-[(1-Benzenesulfonyl-piperidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;2-[(1-Benzenesulfonyl-2,5-dihydro-1H-pyrrole-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid; or,2-[(1-Benzenesulfonyl-pyrrolidine-2-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid;\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the disease state or infection is vascular, cancer-related, diabetes-related, or rheumatoid."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16 wherein the subject is suffering from or susceptible to one or more of acute coronary syndromes, stroke, ischaemic complications of peripheral vascular disease, deep vein thrombosis (DVT), myocardial infarction, coronary artery disease, cerebrovascular disease, peripheral arterial disease, diabetes mellitus, atrial fibrillation, congestive heart failure, pulmonary embolism, and other vascular-related disorders."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the subject is suffering from or susceptible to one or more of human melanoma, hepatocellular carcinoma, breast cancer, lung cancer, ovarian cancer, and other cancers or cancer-related disorders."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the subject is suffering from or susceptible to one or more of rheumatoid arthritis, diabetic retinopathy, and other rheumatoid- or diabetes-related disorders."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the disease state or infection is matrix reorganization-affected."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the disease state or infection is angiogenesis-affected."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the disease state or infection is cell migration-, cell proliferation-, cell colonization-, or metastasis-affected."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the disease state or infection is leukocyte infiltration-affected."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein the disease state or infection is edema-affected."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, where in the subject is suffering from or susceptible to viral infection."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein said viral infection is at least partially attributable to human cytomegalovirus (HCMV), rotaviruses, Piconaviridae viruses, or related viruses."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16 wherein said composition additionally comprises a pharmaceutically acceptable carrier, diluent, or excipient."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein said composition comprises a stereochemically enriched mixture of compounds of the formula."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, wherein said subject is human."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16, where said subject is a non-human animal."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["A compound having the formula:\n
wherein:\n\nR0 is alkylidene;\nR1 is NH(aralkyl), NHSO2aryl, NHSO2alkyl, CH2C(═O)alkoxy, NHC(═O)alkyl, NHC(═O)alkoxy, NHC(═O)aralkoxy, NHSO2R2, or NHC(═O)R2;\nR2 is aryl, alkyl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino;\nEach R3 is independently halo, nitro, aryl, amino, alkyl, alkoxy, NH-Boc, alkylsulfonyl, NHC(═O)alkyl, NHC(═O)aralkyl, or NHC(═O)arylamino;\nEach R4 is independently amino, hydroxy, aralkoxy, NH(aryl), or NHC(═O)aryl;\nR5 is H or alkyl;\nR6 is H or ═O;\nA is SO2, PO2, CO2, or C═O;\nD is optional and may be one or more CH2 groups;\nE is aryl or heteroaryl;\nX is N, O, or S;\nY is CH2, CR7R8, CCH(CH3), or C(CH3)2;\nR7 and R8 are independently H, alkyl, aryl, heteroaryl, alkaryl, or alkyl-heteroaryl;\nn is 0, 1, or 2; and,\nm is 0 or 1,\nwherein the dashed line may represent a double bond when X is N,\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["A composition comprising a compound according to claim 34 and a pharmaceutically acceptable carrier, diluent, or excipient."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["A composition comprising a stereochemically enriched mixture of compounds according to claim 34."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 34 wherein R5 and R6 are each H, Y is CH2, CR7R8, or C(CH3)2, and R0 is —CH2—."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 37 wherein X is O and Y is CH2."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 37 wherein X is S."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 34, where A is C═O or CO2 and E is phenyl."],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 34, where A is SO2."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 41, where E is phenyl and D represents a bond between A and E."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 42, where n equals 0."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 43, where R1 is NHC(═O)R2."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 44, where R2 is aryl, aralkylamino, arylamino, aralkyl, aralkoxy, or alkylamino."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 45, where m=1."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 46, where R4 is hydroxy or aralkoxy."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 42, where n=1."],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 48, where R3 is amino, acetamino, nitro, methyl, phenyl, benzyl, NHC(═O)benzyl, NHC(═O)phenylamino, or methylsulfonyl."],"number":49,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 49, where R1 is NH(aralkyl), NHSO2aryl, CH2C(═O)alkoxy, NHC(═O)alkoxy, NHC(═O)aralkoxy, or NHC(═O)R2."],"number":50,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 50, where R2 is aryl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino."],"number":51,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 48, wherein R3 is nitro and R1 is —NH(aralkyl), —NHSO2aryl, CH2C(═O)alkoxy, —NHC(═O)alkoxy, —NHC(═O)aralkoxy, or —NHC(═O)R2."],"number":52,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 52, wherein R2 is aralkyl, aralkylamino, arylamino, or alkylamino."],"number":53,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 42, where n=2."],"number":54,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 54, wherein R3 is alkyl or halo, R1 is NH(aralkyl), NHSO2aryl, CH2C(═O)alkoxy, NHC(═O)alkoxy, NHC(═O) O-aralkyl or NHC(═O)R2, and R2 is aralkyl, aralkylamino, arylamino, or alkylamino."],"number":55,"annotation":false,"claim":true,"title":false},{"lines":["A compound according to claim 34, wherein the compound is 2-[(3-Benzenesulfonyl-5,5-dimethyl-thiazolidine-4-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid."],"number":56,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating at least one integrin α2β1-affected disease state or infection comprising the step of administering to a subject in need thereof a composition comprising a therapeutically effective amount of a compound having the formula:\n
wherein:\n\nR0 is alkylidene;\nR1 is NH(aralkyl), NHSO2aryl, NHSO2alkyl, CH2C(═O)alkoxy, NHC(═O)alkyl, NHC(═O)alkoxy, NHC(═O)aralkoxy, NHSO2R2, or NHC(═O)R2;\nR2 is aryl, allyl, aralkyl, aralkoxy, aralkylamino, arylamino, or alkylamino;\nEach R3 is independently halo, nitro, aryl, amino, alkyl, alkoxy, NH-Boc, alkylsulfonyl, NHC(═O)alkyl, NHC(═O)aralkyl, or NHC(═O)arylamino;\nEach R4 is independently amino, hydroxy, aralkoxy, NH(aryl), or NHC(═O)aryl;\nR5 is H or alkyl;\nR6 is H or ═O;\nA is SO2, PO2, CO2, or C═O;\nD is optional and may be one or more CH2 groups;\nE is aryl or heteroaryl;\nX is N, O, or S;\nY is CH2, CR7R8, CCH(CH3), or C(CH3)2;\nR7 and R8 are independently H, alkyl, aryl, heteroaryl, alkaryl, or alkyl-heteroaryl;\nn is 0, 1, or 2; and,\nm is 0 or 1,\nwherein the dashed line may represent a double bond when X is N,\n
or a stereoisomer, partial stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid hydrate, or N-oxide thereof."],"number":57,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 16 wherein the subject is administered a therapeutically effective amount of 2-[(3-Benzenesulfonyl-5,5-dimethyl-thiazolidine-4-carbonyl)-amino]-3-(3-benzyl-ureido)-propionic acid."],"number":58,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57 wherein the subject is suffering from or susceptible to one or more of acute coronary syndromes, stroke, ischaemic complications of peripheral vascular disease, deep vein thrombosis (DVT), myocardial infarction, coronary artery disease, cerebrovascular disease, peripheral arterial disease, diabetes mellitus, atrial fibrillation, congestive heart failure, pulmonary embolism, and other vascular-related disorders."],"number":59,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein the subject is suffering from or susceptible to one or more of human melanoma, hepatocellular carcinoma, breast cancer, lung cancer, ovarian cancer, and other cancers or cancer-related disorders."],"number":60,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein the subject is suffering from or susceptible to one or more of rheumatoid arthritis, diabetic retinopathy, and other rheumatoid- or diabetes-related disorders."],"number":61,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein the disease state or infection is matrix reorganization-affected."],"number":62,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein the disease state or infection is angiogenesis-affected."],"number":63,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein the disease state or infection is cell migration-, cell proliferation-, cell colonization-, or metastasis-affected."],"number":64,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein the disease state or infection is leukocyte infiltration-affected."],"number":65,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein the disease state or infection is edema-affected."],"number":66,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, where in the subject is suffering from or susceptible to viral infection."],"number":67,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein said viral infection is at least partially attributable to human cytomegalovirus (HCMV), rotaviruses, Piconaviridae viruses, or related viruses."],"number":68,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57 wherein said composition additionally comprises a pharmaceutically acceptable carrier, diluent, or excipient."],"number":69,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein said composition comprises a stereochemically enriched mixture of compounds of the formula."],"number":70,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, wherein said subject is human."],"number":71,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 57, where said subject is a non-human animal."],"number":72,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}